Nurse Practitioner, Family · Sidney, NY
NPI
1891000329
Since 2010
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
59 River St
Sidney, NY, 13838
Phone (607) 563-8022
Groups this clinician bills Medicare through
Medicare paid, 2024
$19K
411 services
Medicare patients, 2024
222
Average age 71
Drug cost, 2024
$5.6M
7,704 prescriptions
Company payments, 2025
$332
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jennifer M Lavare was code 99214 (office e&m - established), 213 times for 145 patients. In total Jennifer M Lavare billed 411 services in 9 codes, and Medicare paid $19K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 213 | 145 | $54.27 | $12K |
| 99213 Office E&M - Established | Facility | 85 | 64 | $34.99 | $2,974 |
| 99214 Office E&M - Established | Office | 38 | 26 | $67.61 | $2,569 |
| 99211 Office E&M - Established | Facility | 29 | 25 | $4.82 | $140 |
| 99213 Office E&M - Established | Office | 15 | 13 | $56.02 | $840 |
By year: 2022 $22K for 449 services; 2023 $21K for 423 services; 2024 $19K for 411 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jennifer M Lavare prescribed most often to Medicare patients was Ozempic (Semaglutide), with 719 prescriptions and refills. In total Jennifer M Lavare wrote 7,704 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 719 | 1,264 | 177 | $1.2M |
| Trulicity Dulaglutide | 579 | 817 | 118 | $782K |
| Metformin Hcl Er Metformin Hcl | 501 | 1,247 | 141 | $9,087 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 446 | 1,089 | 163 | $79K |
| Jardiance Empagliflozin | 441 | 945 | 118 | $545K |
| Metformin Hcl Generic | 384 | 1,009 | 128 | $3,890 |
| Novolog Flexpen Insulin Aspart | 382 | 874 | 144 | $140K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 320 | 854 | 153 | $42K |
| Tresiba Flextouch U-100 Insulin Degludec | 303 | 745 | 98 | $324K |
| Mounjaro Tirzepatide | 300 | 383 | 70 | $398K |
| Levothyroxine Sodium Generic | 231 | 644 | 81 | $3,639 |
| Humalog Kwikpen U-100 Insulin Lispro | 218 | 529 | 80 | $85K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 179 | 470 | 60 | $213K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 172 | 407 | 68 | $21K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 171 | 376 | 62 | $98K |
Brand drugs: 5,267 claims; generic drugs: 1,343 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jennifer M Lavare $332 ($332 in general payments such as food, travel and fees) from 4 companies. The largest payer was Sequel Med Tech, LLC with $194.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.